Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
5e5 of anti-GPC3 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human Glypican 3 Protein, His Tag (Cat. No. GP3-HA2H7) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). APC signal was used to evaluate the binding activity (QC tested).
Anti-human GPC3 MAb (chimeric mouse-human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Glypican 3, His Tag, premium grade (Cat. No. GP3-H52H4) with an affinity constant of 1.33 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Anti-Human GPC3 MAb (chimeric mouse-human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Glypican 3 (S359F) Protein, His Tag (Cat. No. GP3-H5223) with an affinity constant of 1.96 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| ERY-974 | ERY-974 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
| ECT-204 | ECT-204; JWATM-204 | Phase 2 Clinical | Eureka Therapeutics Inc | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
| GPC3-CAR-T cell therapy(Origincell Medical Technology) | Ori-CAR-001 | Phase 1 Clinical | Carcinoma, Hepatocellular | Details | |
| Anti-GPC3-IRDye800CW | Clinical | Chinese Academy Of Sciences | Details | ||
| CM-350 | CM-350 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Solid tumours | Details |
| IM-83 CAR-T cell therapy | IM-83 | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Liver Neoplasms | Details |
| TC-CAR-031 | TC-CAR-031; TC-CAR031 | Phase 1 Clinical | Zhejiang University | Carcinoma, Hepatocellular | Details |
| GPC3 CAR-T therapy (Hrain Biotechnology) | Phase 2 Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Hepatocellular | Details | |
| CAR-GPC3 T-cell (Drum Tower Hospital) | Phase 2 Clinical | Nanjing Drum Tower Hospital | Carcinoma, Hepatocellular | Details | |
| Anti-GPC3 CAR T-cell therapy (Nanjing University) | Phase 1 Clinical | Nanjing University | Carcinoma, Hepatocellular | Details | |
| GLYCAR T cell therapy (Baylor College of Medicine) | GLYCAR | Phase 1 Clinical | Baylor College Of Medicine | Liver Neoplasms; Rhabdomyosarcoma; Rhabdoid Tumor; Hepatoblastoma; Wilms Tumor; Liposarcoma; Endodermal Sinus Tumor; Carcinoma, Hepatocellular | Details |
| GPC3-T2 CAR-T cell therapy (The Second Affiliated Hospital of Guangzhou Medical University) | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details | |
| Codrituzumab | GC-33; RG-7686; RO-5137382 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
| GPC-3298306 | GPC-3298306 | Phase 2 Clinical | National Cancer Center Of Japan | Ovarian Neoplasms; Carcinoma, Hepatocellular | Details |
| TAK-102 | TAK-102 | Phase 1 Clinical | Noile-Immune Biotech Inc | Solid tumours; Neoplasms | Details |
| CT-0180 | CT-0180 | Phase 1 Clinical | CARsgen Therapeutics Holdings Ltd | Carcinoma, Hepatocellular | Details |
| GPC3-CAR-T cell therapy | CSG-GPC-3; CAR-GPC3 T-cell; GPC3-CAR/CSG-GPC3; anti-GPC-3 CAR T; KJgpc3-001; CT-011 | Phase 1 Clinical | Solid tumours; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details | |
| B010-A | B010-A | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Carcinoma, Hepatocellular | Details |
| CT-017 | CT-017 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Carcinoma, Hepatocellular | Details |
| CT0181 | CT-0181 | Phase 1 Clinical | CARsgen Therapeutics Holdings Ltd | Carcinoma, Hepatocellular | Details |
| GPC3-targeted CAR-T (Peking University) | Phase 1 Clinical | Peking University | Carcinoma, Hepatocellular | Details | |
| CAR (hYP7)-T cells (National Cancer Institute) | Phase 1 Clinical | National Cancer Institute | Liver Neoplasms; Carcinoma, Hepatocellular | Details | |
| Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine) | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd, Guangdong Zhaotai Invivo Biomedicine Co Ltd | Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details | |
| BOXR-1030 | BOXR-1030 | Phase 2 Clinical | Unum Therapeutics Inc | Liver Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Lung Neoplasms; Liposarcoma, Myxoid; Carcinoma, Hepatocellular | Details |
This web search service is supported by Google Inc.
A-Z
